Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 6 months and 12 years old, with a body weight of ≥5 kg;~* Living in the catchment area of the study (within a radius of \~10 km from St. Jude's Clinic, Mbita, Kenya);~* Having microscopically confirmed P. falciparum mono-infection (asexual parasite density 1,000-200,000 µL-1).~Exclusion Criteria:~* Signs and symptoms of severe malaria (according to WHO criteria for severe malaria, (WHO 2012)) or any other severe illness necessitating parenteral treatment;~* Mixed Plasmodium infection;~* Clinically suspected (oedema, jaundice and/or ascites) or reported hepatic and/or renal impairment (any cause, as reported by parents/guardians and/or evident from medical history);~* Having anaemia with an Hb \<6 g/dL;~* Evidence of severe malnutrition (severe wasting: z-score weight for age \<-3 and severe stunting: z-score height for age \<-3 (WHO 2009b));~* Having received anti-malarial therapy in the previous two weeks;~* Known history of hypersensitivity, allergic or adverse reactions to artesunate, artemether-lumefantrine or other artemisinins;~* Participating in other anti-malarial drug intervention studies;~* Previous participation in the PAAL study, e.g. in the previous transmission season (each individual child can only take part in this study once);~* Not being available for follow-up.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Pyronaridine-artesunate (Type: EXPERIMENTAL): pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).